(2014) 130:15798810.1161/CIRCULATIONAHA.114.010389 67
The source of compounded semaglutide sodium is often unknown, which puts patient safety in jeopardy since the quality cannot be ensured or regulated
It is important to note that there is no definitive evidence establishing a permanent taste alteration with GLP-1 therapy, and individual experiences vary considerably
In trial 4, 5.8 % of Semaglutide treated patients discontinued, and 11.6 % of placebo-treated patients ceased the prosecution
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
More concerning are systemic allergic reactions , which affect the body more broadly